Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients

This study is designed to comprehensively explore the role of ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1) in bladder cancer (BC) development and progression. ENPP1 has been implicated in various cancers, with evidence suggesting its involvement in immune evasion, chemoresistance, and poor prognosis. However, its specific function in bladder cancer remains unclear. This research will analyze clinical samples, including tumor tissues and normal adjacent tissues, to evaluate ENPP1 expression through a combination of advanced laboratory techniques such as RNA sequencing, quantitative real-time PCR (qRT-PCR), Western blotting, immunohistochemistry (IHC), and immunofluorescence.

Furthermore, the study will investigate the association between ENPP1 expression and key clinical parameters, including tumor stage, grade, lymph node involvement, metastasis, and patient survival outcomes. Through bioinformatics tools, immune infiltration analysis will be conducted to assess the impact of ENPP1 on immune cells such as CD8+ T cells, dendritic cells, and M2 macrophages, which are crucial in the tumor microenvironment.

The research will also explore the correlation between ENPP1 expression and resistance to common chemotherapeutic agents, particularly gemcitabine and cytarabine, using drug sensitivity data from public databases. By identifying the molecular mechanisms by which ENPP1 influences immune responses and chemoresistance, the study aims to provide valuable insights into potential therapeutic targets for bladder cancer treatment. Ultimately, this research may contribute to the development of personalized therapies for bladder cancer patients based on ENPP1 expression.

Inclusion criteria

• Adults aged 18 years or older.
• Histologically confirmed diagnosis of bladder cancer.
• Measurable disease as per RECIST criteria.
• Adequate organ function as defined by laboratory tests (e.g., liver, kidney, and hematologic function).
• ENPP1 expression level determined via biopsy or previous analysis.
• Written informed consent provided.

Exclusion criteria

• History of other malignancies within the past 5 years, excluding non-melanoma skin cancer or in situ carcinoma.
• Prior treatment with ENPP1 inhibitors or similar targeted therapies.
• Active or uncontrolled infections.
• Pregnant or breastfeeding women.
• Known autoimmune disorders or conditions requiring immunosuppressive therapy.
• Inability to comply with the study protocol or procedures.